ESA Stakeholders May Find Clues About Medicare Revisions In Device NCDs
This article was originally published in The Pink Sheet Daily
Executive Summary
Stakeholders would likely need to develop new data to convince CMS to alter the recently issued national coverage determination on ESA usage in non-renal settings, based on general track record in NCDs.
You may also be interested in...
FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.
FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.
Requests To Reopen Medicare ESA Policy Are Not Yet Persuasive To CMS
Agency advises stakeholders that they must present new data or analysis that current data was materially misinterpreted in order to gain a reconsideration of the erythropoeisis-stimulating agents coverage policy.